Ajovy (fremanezumab-vfrm) NDC 51759-204

NDC codes

FDA NDC Directory

Product NDC (as listed)51759-204Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51759-0204Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51759-204-10	51759020410	1 SYRINGE, GLASS in 1 CARTON (51759-204-10) / 1.5 mL in 1 SYRINGE, GLASSMarketed from Sep 15, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ajovy
Generic name (nonproprietary): fremanezumab-vfrm
Active ingredients: Fremanezumab — 225 mg/1.5mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761089
Marketing start: Sep 15, 2018
Listing expires: Dec 31, 2027
Identifiers: Product ID 51759-204_4e729b85-d3b0-445d-9cba-9326b4e2291fSPL ID 4e729b85-d3b0-445d-9cba-9326b4e2291fSPL set ID 98e344ea-5916-4947-b6f2-4a76ccc04b6bRxCUI 2056695, 2056700, 2287903, 2287905UNII PF8K38CG54

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451759020410 followed by a unit qualifier and the quantity

Package 51759-0204-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 5, 2026.

Indications (excerpt from the label)

AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761089

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761089
Product	Strength	Form · route	Labeler	Product NDC
Ajovyfremanezumab-vfrm	Fremanezumab 225 mg/1.5mL	InjectionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-202